isoproterenol has been researched along with cannabidiol in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Gajo, B; Harasim-Symbor, E; Kasacka, I; Malinowska, B; Pędzińska-Betiuk, A; Schlicker, E; Toczek, M; Weresa, J | 1 |
2 other study(ies) available for isoproterenol and cannabidiol
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Chronic cannabidiol treatment reduces the carbachol-induced coronary constriction and left ventricular cardiomyocyte width of the isolated hypertensive rat heart.
Topics: Adrenergic beta-Agonists; Animals; Antihypertensive Agents; Cannabidiol; Carbachol; Cell Size; Coronary Vessels; Disease Models, Animal; Hypertension; Hypertrophy, Left Ventricular; Isolated Heart Preparation; Isoproterenol; Myocytes, Cardiac; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Vasoconstriction; Vasoconstrictor Agents; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |